Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Intapp Insider Nancy L. Harris Sells $290K of Stock
Nancy L. Harris sold 6,512 shares of Intapp, Inc. at $43.77 to $45.00 a share (average $44.56) in 3 transactions, worth $290K in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 34,907 (-8.5%).
AIRO Group Holdings reported revenue of $69.6 million for the nine months ended September 30, 2026, a significant increase from $42.6 million in the prior year period. Despite higher gross profits, the company incurred a net loss of $29.4 million due to increased research and development and general administrative expenses.
BioCardia, Inc. reported a net loss of $5.7 million for the nine months ended September 30, 2026, compared to a $6.2 million loss in the prior year period. The company ended the quarter with $2.2 million in cash and cash equivalents, supported by $5.3 million in proceeds from common stock sales during the year.
Cyngn Inc. reported a net loss of $18.8 million for the nine months ended September 30, 2026, compared to $17.8 million in the prior year period, despite a significant increase in revenue to $405,527. The company strengthened its cash position through $17.9 million in financing activities, including at-the-market and public stock offerings, ending the period with $3.1 million in cash and $31.8 million in short-term investments.
Knightscope, Inc. reported a significant decrease in cash and cash equivalents from $20.6 million at the end of 2025 to $6.8 million as of September 30, 2026. The company's total assets increased to $52.2 million, primarily driven by a substantial rise in goodwill and intangible assets following acquisitions, while management expressed substantial doubt about the company's ability to continue as a going concern.
United States Antimony Corp reported a significant increase in net loss to $20.7 million for the nine months ended September 30, 2026, compared to $4.1 million in the prior year, driven by a sharp rise in operating expenses and mineral exploration costs. Despite the loss, the company strengthened its balance sheet through common stock issuances, ending the period with $171.9 million in total stockholders' equity.
Relmada Therapeutics reported a net loss of $45.8 million for the nine months ended September 30, 2026, compared to $37.5 million in the prior year, driven by increased research and development costs. The company significantly strengthened its balance sheet through common stock issuances, ending the period with $202.1 million in cash and short-term investments.
Cisco reported record first quarter fiscal 2027 revenue of $18.5 billion, a 24% increase year-over-year, driven by high demand for AI infrastructure and networking technology. The company raised its full-year fiscal 2027 revenue guidance to a range of $74.8 billion to $75.8 billion and increased its AI infrastructure revenue expectations from hyperscalers to $9 billion.
Term
Q1 2027
“In Q1, we delivered the strongest revenue and non-GAAP earnings per share growth rates for Cisco in over 15 years. Organizations are turning to Cisco for our trusted, market-defining technology and our expertise to help them scale, secure and optimize their environments for the agentic AI era. We are in the very early stages of a multi-year networking supercycle, and we're confident in our ability to continue capturing the multi-billion-dollar opportunity it represents for Cisco.”
Chuck Robbins, chair and CEO of Cisco
“Q1 FY27 was another record quarter for Cisco, with revenue, non-GAAP operating margin, and non-GAAP EPS all exceeding the high end of our guidance ranges. The strength of our Q1 performance gives us confidence to raise our revenue and non-GAAP EPS guidance for FY27. As our business continues to scale, we are unlocking significant operating leverage which is enabling us to grow earnings much faster than revenue. Looking ahead, we remain focused on delivering durable growth and driving continued capital returns.”
Yvonne Genovese, EVP, Bus. & Tech. Insights, sold 524 shares of Gartner Inc at $190.30 a share, worth $99.7K in total on Nov 9, 2026. Shares held after the trade: 5,684 (-8.4%).
Genpact Limited held a special general meeting of shareholders on November 10, 2026, where shareholders approved a proposal to change the company's jurisdiction of incorporation from Bermuda to the State of Delaware. The domestication involves discontinuing as a Bermuda exempted company and continuing as a Delaware corporation.
Hyatt Hotels $400M Debt Financing with Computershare Trust Company, N.A.
Hyatt Hotels Corporation completed a public offering of $400 million in 5.950% Senior Notes due 2033. The company received net proceeds of approximately $395.3 million, which it intends to use alongside excess cash to repay its outstanding 5.750% notes due 2027 and for general corporate purposes.
Vuzix Corp reported total sales of $0.7 million for the quarter ended September 30, 2026, down from $1.2 million in the prior year period. The company experienced a net loss of $8.4 million for the quarter and $23.1 million for the first nine months of 2026, while maintaining a cash balance of $9.2 million.
AmpliTech Group reported a net loss of $6.5 million for the nine months ended September 30, 2026, compared to a $3.8 million loss in the prior year period. Despite a slight decrease in nine-month revenue, the company significantly strengthened its balance sheet, increasing cash and marketable securities to over $30 million following successful rights and direct offerings.
EyePoint, Inc. reported a significant increase in net loss to $274.9 million for the nine months ended September 30, 2026, driven primarily by a surge in research and development expenses to $237.4 million. Total revenues declined sharply from $30.8 million to $2.0 million year-over-year, largely due to the absence of significant license and collaboration revenue seen in 2025.
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on genetic medicines for rare diseases. As of September 30, 2026, the company is classified as a non-accelerated filer and smaller reporting company with 111,660,283 shares of common stock outstanding.
HireQuest reported third quarter 2026 financial results, with total revenue increasing 4.0% to $8.8 million. Net income decreased to $1.7 million, or $0.12 per diluted share, primarily due to a $1.3 million write-down of notes receivable related to the repossession of a franchised location.
Term
Q3 2026
“Our third quarter results reflect continued momentum across our core commercial staffing brands, as improving demand delivered another quarter of year-over-year revenue growth. Our franchise model continues to demonstrate its resilience, allowing us to grow alongside our franchisees as they benefit from a strengthened labor market.”
Rick Hermanns, HireQuest’s President and Chief Executive Officer
“We believe the improving demand environment we have seen throughout 2026 positions our franchisees well as we close out the year and look ahead to 2027. We have a strong balance sheet and ample liquidity, and we remain focused on disciplined capital allocation as we work to deliver consistently profitable results and enhanced value for our shareholders.”
Rick Hermanns, HireQuest’s President and Chief Executive Officer
Zevia PBC Director David J. Lee Sells $231K of Stock
David J. Lee, Director, sold 179,589 shares of Zevia PBC at $1.29 a share, worth $231K in total on Nov 9, 2026. Shares held after the trade: 100,373 (-64.1%).
Solésence reported record third quarter 2026 financial results, with revenue increasing 38% year-over-year to $20.2 million. The company achieved its highest-ever quarterly net income of $3.7 million, driven by operational excellence and strong demand from brand partners.
Term
Q3 2026
“We’re very pleased that Solésence delivered solid top line growth as well as steady operational and strategic progress in the third quarter, driven by key milestones across our Transform and Transcend framework. Most notably, we reached a major turning point by completing the primary investment and implementation phase of our first pillar, operational excellence. This elevated capacity and efficiency position us to meet robust demand from our brand partners today while seamlessly scaling for tomorrow. Paired with our continued innovation in novel formulations and expanding global presence, Solésence is uniquely positioned to deliver long-term, profitable growth and lead the market in meeting evolving consumer needs.”
Kevin Cureton, President and CEO
“By pairing record revenue and net income with strong margin expansion, we have positioned Solésence for sustained growth. The operational and financial improvements achieved throughout 2026 provide a strong foundation as we look ahead to 2027.”
ADARx Pharmaceuticals reported Q3 2026 financial results, highlighting a cash position of $611.8 million following its IPO and concurrent private placement with AbbVie. The company is advancing three Phase 2 clinical trials for agazisiran and received FDA Fast Track designation for onvuzosiran in hereditary angioedema.
“We have made significant progress across our pipeline of next-generation siRNA therapeutics, bolstered by the successful completion of our IPO and concurrent private placement. These financings provide the resources to advance three clinical-stage programs in parallel, bring two advanced preclinical candidates into the clinic, and support additional IND filings as we expand our pipeline.”
Zhen Li, Ph.D., President and Chief Executive Officer of ADARx
“As the siRNA field evolves, we see tremendous opportunity to expand the range of diseases these therapeutics can address. We believe that our progress with differentiated liver-targeted programs and targeted delivery to extrahepatic tissues positions us to advance our mission of delivering life-changing treatments to patients with unmet medical needs.”
Zhen Li, Ph.D., President and Chief Executive Officer of ADARx
Immix Biopharma, Inc. reported a significant increase in cash and cash equivalents to $320.3 million as of September 30, 2026, compared to $93.9 million at year-end 2025. The company's accumulated deficit grew to $140.0 million, driven by nine-month operating expenses including $22.4 million in general and administrative costs and $16.9 million in research and development.
Digimarc reported third quarter 2026 financial results, with total revenue of $6.4 million and a net loss of $8.1 million. The company noted that momentum is building with new customers in retail and CPG, though ARR decreased to $10.8 million primarily due to the expiration and step-down of two major commercial contracts.
“Last quarter we said our new execution focus was starting to show results. Since then, many of those results moved from pipeline to signed business earlier than expected, with new customers committing to our solutions across retail and CPG.”
Paul Carreiro, Digimarc CEO
“Our commercial leadership team is mostly in place, and our focus is clear: turn this momentum into recurring and predictable revenue growth in 2027.”
Zimmer Biomet Holdings $500M Debt Financing with Barclays Capital Inc.
Zimmer Biomet Holdings, Inc. completed a dual-currency public offering of senior notes, consisting of $500 million of 5.850% notes due 2036 and €500 million of 4.375% notes due 2033. The proceeds are intended to be used for general corporate purposes, which may include the repayment of existing 2.425% notes due 2026 and 4.700% notes due 2027.
Newsmax reported record Q3 2026 revenue of $69.0 million, a 52.5% year-over-year increase, driven by strong affiliate fees and a $14 million service revenue termination fee. The company achieved net income of $15.2 million and Adjusted EBITDA of $19.0 million, marking its second consecutive profitable quarter. Additionally, the company announced the resignation of director Nancy G. Brinker and the appointment of Carla Sands to the Board.
Term
Q3 2026
“The third quarter was the strongest in our history as a public company. Setting aside the one-time revenue item, we delivered our fastest revenue growth since our listing and a second consecutive profitable quarter.”
Christopher Ruddy, Chief Executive Officer of Newsmax
“Our third quarter results reflect the operating leverage we are building across the business, with affiliate and licensing growth continuing to shift our revenue mix toward our highest-margin streams.”
Darryle Burnham, Chief Financial Officer of Newsmax
OpenWorld, Inc. reported its first quarterly results as a Nasdaq-listed company following its reverse takeover of VerifyMe. The company reported revenue of $7.4 million and a GAAP net loss of $10.2 million, highlighting a strategic shift toward high-margin real-world asset (RWA) tokenization which contributed $6.4 million to the quarterly revenue.
Term
Q3 2026
“Q3 2026 was a defining quarter as we completed our transition to the public markets and accelerated our evolution into a high-margin RWA platform and major deal-origination company.”
Matthew Shaw, Chairman and Chief Executive Officer
“Revenue from our RWA business grew from zero a year ago to more than $6 million in the 2026 third quarter and $9 million for the first nine months of the year, while we maintained exceptional gross margins of more than 80%.”
Matthew Shaw, Chairman and Chief Executive Officer
Assurant EVP, Pres, Global Housing Ryan Lumsden Sells $1.25M of Stock
Ryan Lumsden, EVP, Pres, Global Housing, sold 3,901 shares of Assurant, Inc. at $319.37 a share, worth $1.25M in total on Nov 10, 2026. Shares held after the trade: 13,432 (-22.5%).
Journey Medical Corporation reported third quarter 2026 financial results, featuring total revenues of $19.0 million, an 8% increase year-over-year. Growth was primarily driven by its oral rosacea treatment, Emrosi, which saw an 84% revenue increase to $9.0 million. The company's net loss narrowed to $1.3 million compared to $2.3 million in the prior-year period.
“We continued to make progress during the third quarter, delivering year-over-year revenue growth, a higher gross margin, and positive EBITDA. Third quarter sales of Emrosi®, our best-in-class oral rosacea treatment, increased by 84% compared to the prior-year period, driven by growth in prescription demand and continued improvement in the mix of prescriptions reimbursed by health plans.”
Claude Maraoui, Journey Medical’s Co-Founder, President and Chief Executive Officer
“Building on this progress and with over $22 million in cash, we believe we are well-positioned to advance our mission of delivering value to our dermatology customers and their patients while building long-term shareholder value.”
Claude Maraoui, Journey Medical’s Co-Founder, President and Chief Executive Officer
Fennec Pharmaceuticals reported a significant increase in total revenue to $19.6 million for Q3 2026, driven by PEDMARK product sales. The company achieved net income of $4.6 million compared to a net loss in the prior year, supported by a decrease in G&A expenses and improved operating margins. Cash reserves stood at $48.7 million, which management expects will be sufficient to fund operations based on the current plan.
Elite Pharmaceuticals reported net income of $23.2 million for the six months ended September 30, 2026, a significant increase from $7.8 million in the prior year period, largely driven by a $9.8 million gain from the change in fair value of derivative warrants. While six-month revenue slightly decreased to $72.4 million, the company maintained a strong cash position of $34.9 million and significantly reduced its total liabilities from $39.4 million to $22.1 million.
Nuwellis, Inc. reported net sales of $6.58 million for the nine months ended September 30, 2026, a 12.6% increase over the prior year. Despite improved gross margins, the company incurred a net loss of $11.34 million, driven by higher operating expenses and significant financing-related costs, though this was an improvement from the $15.10 million loss in the same period of 2025.
Viasat CAO Camellia E. FitzGerald Sells $2.8M of Stock
Camellia E. FitzGerald, CAO, sold 37,500 shares of Viasat Inc at $74.55 a share, worth $2.8M in total on Nov 10, 2026. Shares held after the trade: 12,958 (-74.3%).